We support cure research and development, along with impact strategies to enable affordable access.
Thirty-seven million people living with HIV worldwide, including 1.8 million children.
Eighteen million new cancer cases in 2018 with over 9.5 million deaths worldwide.
Six thousand genetic disorders, many of which are fatal or debilitating.
The price for a one-time advanced therapy is $350,000+, not including hospital costs.
These are some of the statistics that demonstrate why cures are needed and why it is important to develop impact strategies, so cures become affordable and accessible to all in need around the world. These pages highlight some of our projects.
As the technology that enables cure medicines evolves, it is important that specific curative medicines are developed and manufactured affordably so they become accessible to all in need.
We support the development of advanced medicinal cure candidates for specific diseases.
Here’s how we do this:
- Conducting, collaborating, and supporting basic research
- Facilitating and accelerating pre-clinical and clinical development of cure candidates
- Supporting pivotal clinical trials and regulatory approval of cure candidates
- Enabling innovation and implementation of technologies that are important for the manufacture and application of advanced medicinal cures
Currently, our highest priority cure project candidate is an anti-HIV duoCAR-T cell therapy for people living with HIV.
As advanced medicinal therapies are developed, it becomes ever more important to ensure that they are accessible to all who need them.
We support impact projects that enable advanced medicine therapy to be manufactured and distributed affordably so they become widely accessible.
One way to do this is by supporting place-of-care manufacturing models, where personalized medicines are manufactured at or near the clinical center at a fraction of the cost of current modalities.
Here’s how we do this:
- Advancing the place-of-care manufacturing model to improve the affordability and accessibility of cures
- Supporting the development of innovative technologies that enable affordable access of advanced medicinal cures
- Facilitating clinical translation of safety and efficacy validated cure candidates in diverse, marginalized and impoverished communities, including low- and middle-income countries (LMICs)
Currently, we are working towards implementing gene therapy clinical trials in areas of the world where diseases such as Sickle Cell Disease, β-Thalassemia and HIV are major health problems – such as countries in Africa and in India.